[Federal Register Volume 71, Number 33 (Friday, February 17, 2006)]
[Notices]
[Pages 8597-8598]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-2357]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

[[Page 8598]]


ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use

Barry R. O'Keefe et al. (NCI)
U.S. Provisional Application No. 60/741,403 filed 01 Dec 2005 (HHS 
Reference No. E-025-2006/0-US-01).
Licensing Contact: Sally H. Hu, Ph.D., M.B.A.; 301/435-5606; 
[email protected].

    The invention provides for a composition of an anti-viral 
polypeptide, Griffithsin, glycosylation-resistant Griffithsin, and 
related conjugates, compositions, nucleic acids, vectors, host cells, 
antibodies and methods of production and use. More specifically, 
Griffithsin inhibits viral binding, fusion and entry into the host 
cells by binding to viral envelope gp120. Thus, subject invention can 
be developed as an inhibitor therapeutically or prophylactically 
against retroviral infections including HIV-1 and HIV-2 as well as FIV, 
SIV, MLV, BLV, equine infectious virus, avian sarcoma viruses, and 
HTLV. Subject invention also can be developed as an inhibitor against 
non-retroviruses infectious such as influenza virus, including H5N1, 
SARS, Hepatitis C, and Ebola, measles, varicella, human herpes viruses 
and others. In addition, Griffithsin can be used in combination with 
other anti-viral agents to treat patients who have drug-resistant 
virus.
    In addition to licensing, the technology is available for further 
development through collaborative research opportunities with the 
inventors.

Discovery of Tropolone Inhibitors of HIV-1 Integrase That Can Be Used 
for the Treatment of Retroviral Infection, Including AIDS

Yves Pommier, Christophe Marchand, Elena Semenova, Allison Johnson 
(NCI).
U.S. Provisional Application No. 60/741,769 filed 01 Dec 2005 (HHS 
Reference No. E-308-2005/0-US-01).
Licensing Contact: Sally H. Hu, Ph.D., M.B.A.; 301/435-5606; 
[email protected].

    This invention provides pharmaceutical compositions comprising one 
or more HIV-1 integrase inhibitor compounds, as well as methods for 
treatment or prevention of HIV infection. These compounds are alpha-
hydroxytropolone or its salt, solvate or hydrate, and they have been 
shown to inhibit the integrase by interfering with the enzyme catalytic 
site by chelating magnesium ions, and have been shown to inhibit the 
strand transfer reaction. Integrase is an important target for AIDS 
therapy since it is critical for viral replication, and does not have 
cellular counterparts, which can potentially reduce toxic side effects. 
Thus, the compounds of this invention can be developed as novel anti-
viral agents that can be used in combinational therapy, especially 
since they might be less toxic than other anti-viral agents.
    In addition to licensing, the technology is available for further 
development through collaborative research opportunities with the 
inventors.

    Dated: February 10, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
 [FR Doc. E6-2357 Filed 2-16-06; 8:45 am]
BILLING CODE 4140-01-P